Clay Siegall’s Contributions Towards Helping Cancer Patients

Even though numerous individuals and companies engage in cancer research, Clay Siegall, the CEO Seattle Genetics is recognized worldwide for his contributions. Since he started his biomedical career, Siegall focused on enhancing the lives of cancer patients. Besides his active engagement in research and publishing scientific papers, he serves as the President and the Chairman of Seattle genetics since 2002. He co-founded the company back in 1998 and has led it actively to its current status. Under his effective leadership, Seattle Genetics has undertaken different kinds of cancer research, published papers, developed drugs and introduced effective ground-breaking cancer therapies.


Clay Siegall holds a Ph. D. in Genetics from George Washington University and he has had great accomplishments since then. He started his biomedical career at Bristol-Myers Squibb Pharmaceuticals Research Institute as a Senior Research Investigator before he earned the position of a Principal Scientist. Due to his relentless effort and notable contributions, Siegall was admitted as a Biotechnology Fellow and Staff Fellow at the National Cancer Institute. His education background and extensive experience in cancer research were vital for his current position in Seattle Genetics.


Siegall’s career and professional accomplishments are driven by passion and his dedication to alleviating pain and suffering experienced by cancer patients. As a result, he has initiated cutting-edge research aimed at gaining a deeper understanding of cancer and coming up with effective treatment options. His effort has transformed Seattle Genetics into a world leader in terms of cancer research and drug developments. One of the noteworthy achievements of Seattle Genetics is successful development and approval of its first antibody-drug conjugate, ADCETRIS. The drug secured FDA approval in 2011 and it has been accepted in more than sixty countries. The steadfast commitment to development of the effective drug is a proof of his passion and insatiable desire to help cancer patients.


He has received numerous honors and Awards for his scientific and medical research. So far, he has published more than 70 articles and research papers sharing his discovery with the scientific communities. Besides, he is a recognized member of the editorial boards of scientific journals that publish articles and scientific research findings.